Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies, Ltd., a biotechnology company in Israel, says that regulatory T suppressor cells (Tregs) are active in HIV infection and tend to suppress cellular immunity. He adds that Programmed cell death protein 1 (PD-1) and Cytotoxic T-lymphocyte antigen 4 (CTLA-4) are also up-regulated on HIV-specific CD4 T cells and that this expression correlates with an increase measured HIV. Dr. Michael Har-Noy notes that intravenous AlloStimTM infusion shuts off Tregs that inhibit cellular immunity against various cancers and enables these cells to morph into non-suppressor types. Dr. Michael Har-Noy believes that, in the face of AlloStimTM infusion, down regulation of PD-1 and CTLA-4, as well as Treg function reversal, might create an immune environment that would help a patient to clear the HIV.
Dr. Michael Har-Noy says that CD40 ligand (CD40L), a member of the tumor necrosis factor group of cell surface molecules, is expressed on viral particles and facilitates the activation of dendritic cells and macrophages. This activation leads to increased activation of CD4+ T cells, thereby promoting the replication of latent HIV in these lymphocytes. Dr. Michael Har-Noy indicates that intravenous AlloStimTM infusion greatly increases CD40L expression. Since CD40L expression helps the immune system control viral replication by inducing HIV-suppressive chemokines and increasing the production of anti-HIV antibodies and cytotoxic T-cells, Dr. Michael Har-Noy concludes that AlloStimTM infusion may greatly enhance the ability of a patient's immune system to suppress the HIV.
Lastly, Dr. Michael Har-Noy notes that natural killer (NK) cells are a vital part of a person's innate immune response against viral infections. NK cell-mediated cytolytic activity is impaired in HIV-infected patients. AlloStimTM infusion in cancer patients activates NK cells. Therefore, Dr. Michael Har-Noy concludes that by enhancing NK cell function, AlloStimTM infusion may impose significant immunologic pressure on the HIV.
Dr. Michael Har-Noy is now conducting a Phase I/II study of AlloStimTM administration in HIV-infected patients. This study is part of a broad Compassionate Use program and is being conducted in Bangkok, Thailand. For more information, visit www.immunocare.net